Trial
NCT00343759
Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Pennsylvania
Collaborators
—
Condition
Breast Cancer
Intervention
Lapatinib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-12-11